News MFN model for Medicaid revealed by CMS The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid.
News GLP-1s feature in second batch of national priority vouchers GLP-1 drugs for weight loss, cancer, and rare diseases feature among the latest crop of medicines awarded priority vouchers by the FDA.
News Novo, Lilly sign MFN pricing deal with Trump administration The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
News J&J adds first new indication for Caplyta since takeover Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.
News Dismay as FDA declines to approve Biohaven's ataxia drug Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, in another sign of a tougher stance by the agency.
News UCB bags FDA okay for first drug to treat rare disease TK2d People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.
News Recordati gets €10.9bn takeover bid from private equity firm Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
